文献速递胸部肿瘤

埃万妥单抗联合化疗±拉泽替尼治疗奥希替尼进展后EGFR突变晚期NSCLC:III期MARIPOSA-2研究主要结果

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
PubMed 文献 · Ann Oncol · 2023-10-23

MARIPOSA-2研究纳入657例奥希替尼进展后EGFR突变(19外显子缺失或L858R)局部晚期或转移性NSCLC患者,按2:2:1随机接受埃万妥单抗-拉泽替尼-化疗、化疗或埃万妥单抗-化疗。埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗较化疗显著延长无进展生存期(HR 0.48和0.44,均P<0.001;中位6.3和8.3 vs 4.2个月)。

要点

  • 埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗较化疗显著改善PFS(HR 0.48和0.44,均P<0.001)。
  • 客观缓解率:埃万妥单抗-化疗64%、埃万妥单抗-拉泽替尼-化疗63%,均高于化疗36%(均P<0.001)。
  • 含埃万妥单抗方案主要不良事件为血液学、EGFR及MET相关毒性;埃万妥单抗-化疗血液学不良事件率低于埃万妥单抗-拉泽替尼-化疗。

核心结论

  • 在奥希替尼进展后治疗选择有限的人群中,埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗较化疗改善PFS和颅内PFS。
  • 改良的埃万妥单抗-拉泽替尼-化疗方案需要更长时间随访。

研究设计与样本

  • 全球III期随机试验,657例奥希替尼进展后EGFR突变(19外显子缺失或L858R)局部晚期或转移性NSCLC患者按2:2:1随机接受埃万妥单抗-拉泽替尼-化疗、化疗或埃万妥单抗-化疗。
  • 双主要终点为埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗对比化疗的无进展生存期(PFS)。
  • 研究期间埃万妥单抗-拉泽替尼-化疗组观察到血液学毒性,需调整方案为卡铂完成后再开始拉泽替尼。

主要发现

  • PFS:埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗对比化疗的疾病进展或死亡HR分别为0.48和0.44(均P<0.001),中位PFS分别为6.3和8.3 vs 4.2个月。
  • 研究者评估PFS:埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗对比化疗的疾病进展或死亡HR分别为0.41和0.38(均P<0.001),中位PFS分别为8.2和8.3 vs 4.2个月。
  • 客观缓解率:埃万妥单抗-化疗64%、埃万妥单抗-拉泽替尼-化疗63%,化疗36%(均P<0.001)。
  • 颅内PFS:埃万妥单抗-化疗和埃万妥单抗-拉泽替尼-化疗对比化疗的中位颅内PFS分别为12.5和12.8 vs 8.3个月,颅内疾病进展或死亡HR分别为0.55和0.58。
  • 含埃万妥单抗方案主要不良事件为血液学、EGFR及MET相关毒性;埃万妥单抗-化疗血液学不良事件率低于埃万妥单抗-拉泽替尼-化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 改良的埃万妥单抗-拉泽替尼-化疗方案需要更长时间随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. PATIENTS AND METHODS: A total of 657 patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on osimertinib were randomized 2 : 2 : 1 to receive amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. The dual primary endpoints were progression-free survival (PFS) of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy. During the study, hematologic toxicities observed in the amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start lazertinib after carboplatin completion. RESULTS: All baseline characteristics were well balanced across the three arms, including by history of brain metastases and prior brain radiation. PFS was significantly longer for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, respectively]. Consistent PFS results were seen by investigator assessment (HR for disease progression or death 0.41 and 0.38 for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 versus 8.3 months for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial disease progression or death 0.55 and 0.58, respectively). Predominant adverse events (AEs) in the amivantamab-containing regimens were hematologic, EGFR-, and MET-related toxicities. Amivantamab-chemotherapy had lower rates of hematologic AEs than amivantamab-lazertinib-chemotherapy. CONCLUSIONS: Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023. PMID: 37879444. doi:10.1016/j.annonc.2023.10.117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。